- 中文名称
CBLB 抗体
- 英文名字
- CBLB Antibody
- 供应商
- Aviva Systems Biology
- 产品货号
- aviva-OAAJ07227-100UL
- 产品报价
- ¥询价/100uL

- 产品说明书
- 点击查看
- 购买方式
- 银行转账、电汇、支票、现金,在线支付宝及网银支付,或直接与我们电话联系。本公司所有产品仅供科研使用,不用于临床诊断。
- 产品新闻

- 背景资料
- The Casitas B lineage lymphoma (Cbl) proteins (in mammals these are c-Cbl, Cbl-b, and Cbl-c) are a family of single subunit RING finger protein-ubiquitin E3 ligases that contain multiple protein interaction motifs. All Cbl proteins have a highly conserved N-terminal tyrosine kinase-binding (TKB) domain that mediates interactions between Cbl proteins and phosphorylated tyrosine residues on Cbl substrates. C-terminal to the RING finger, Cbl proteins have proline-rich domains that mediate interactions with SH3 domain-containing proteins. Phosphorylated tyrosine residues mediate interactions with SH2 domain-containing proteins such as the p85 subunit of PI3K. These protein-protein interaction motifs allow Cbl family proteins to function as adaptor proteins (2). This adaptor function contributes to the E3-dependent activities of Cbl proteins by targeting specific substrates for ubiquitination and degradation. The adaptor function also contributes to non-E3-dependent activities, such as the recruitment of proteins involved in receptor tyrosine kinase internalization, localization of Cbl proteins to specific subcellular compartments, and activation of discrete signaling pathways. Cbl-b is an E3 ubiquitin ligase with a domain organization nearly identical to that of c-Cbl. The role of Cbl-b in hematopoietic cell physiology is well documented. Cbl-b expression is important for the downregulation of TCR expression during antigen recognition. Cbl-b also acts as a potent negative regulator of the CD28 signaling cascade to Vav and Rac1 through its ability to ubiquitinate the p85 regulatory subunit of PI3K. As a critical regulator of clonal anergy in T lymphocytes, Cbl-b mRNA and protein are upregulated in T cells following calcium mobilization and calcineurin activation. Cbl-b-deficient T cells are resistant to anergy induction. The molecular events governing this phenotype are thought to be linked to defects in the ubiquitination of PLCγ1 and PKCθ since the degradation of these signaling molecules, which occurs following restimulation of wild-type anergic T cells, fails to occur in Cbl-b-deficient T cells.
- 应用类型
- WB, IHC
- 免疫原
- A synthesized peptide derived from human CBLB
- 来源宿主
- Rabbit
- 反应性
- 该CBLB 抗体的反应性请参考该产品的说明书
- 保存建议
- Store at -20°C. Stable for 12 months from date of receipt.
- 其他
- Aviva Systems Biology总部位于加利福尼亚州圣迭戈,在中国北京设有办公室,专注于为研究需求提供多克隆和单克隆抗体、ELISA试剂盒、蛋白质和定制服务。Aviva Systems Biology生产了24,000种经过验证的多克隆抗体,并提供近20,000种ELISA试剂盒,定制实验室服务包括蛋白表达和纯化、抗体开发,以及ELISA的开发、验证和生产。Aviva Systems Biology为与独特物种和靶标相关的研究提供独特工具,研究领域包括转录因子、癌症、心血管、细胞生物学、DNA损伤和修复、表观遗传学、信号转导、细胞分化、干细胞生物学等等。

- 注意
-
该页面的中文产品信息的翻译,仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前,请浏览说明书确认。
-